Organization and Application of ECLS Therapy—A Nationwide Survey in German Cardiosurgical Departments

Alexander Assmann¹,*, Udo Boeken¹,*, Stefan Klotz², Wolfgang Harringer³, Andreas Beckmann⁴

¹Department of Cardiovascular Surgery, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
²Department of Cardiac and Thoracic Vascular Surgery, University Hospital of Schleswig-Holstein, Lübeck, Germany
³Clinic for Cardiac, Thoracic and Vascular Surgery, Klinikum Braunschweig gGmbH, Braunschweig, Germany
⁴German Society for Thoracic and Cardiovascular Surgery, Berlin, Germany


Abstract

Background  In context of the multidisciplinary German scientific guideline “Use of extracorporeal circulation (extracorporeal life support [ECLS]/extracorporeal membrane oxygenation) for cardiac and circulatory failure,” a nationwide survey should depict the status of organization and application of ECLS therapy in Germany.

Methods  Between June and October 2017, a standardized questionnaire consisting of 30 items related to ECLS therapy was sent to all German cardiosurgical departments, and all returned results were analyzed and evaluated.

Results  The return rate amounted to 92.9% (78 out of 84 departments). In the participating departments, ECLS therapy is subject to different responsibilities, and exhibits divergent processes and various ways for specialization of the involved personnel. This also concerns local application standards, such as cannulation strategies, anticoagulation management, left ventricular unloading, antiwatershed treatment, and weaning from circulatory support.

Conclusion  This nationwide survey underlines the necessity of a multidisciplinary guideline concerning ECLS therapy.

Introduction

Extracorporeal life support (ECLS) and extracorporeal membrane oxygenation (ECMO) have become important tools for the treatment of patients suffering from circulatory and pulmonary failure. Nowadays, miniaturization and simplification of device components for extracorporeal circulation enable fast and frequent application in the operation room, catheterization laboratory, or intensive care units. These devices can also be utilized to establish extracorporeal circuits in out-of-hospital scenarios and for safe transport of patients with circulatory or pulmonary failure.¹,² Most indications for extracorporeal circulation are patients with therapy-refractory cardiogenic shock, acute lung failure or embolism, and severe hypothermia.³–⁷ Concerning ECLS under resuscitation due to cardiac disease, there seems to be an improvement of patients’ outcome regarding survival and neurological impairment.⁸,⁹ ECLS and ECMO particularly serve as a bridging therapy in emergency situations until further decisions or treatment options follow.

Keywords  ► cardiopulmonary bypass  ► extracorporeal life support  ► extracorporeal membrane oxygenation  ► cardiac and circulatory failure  ► statistics  ► survey

© 2019 Georg Thieme Verlag KG Stuttgart · New York
ISSN 0171-6425.

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Although ECLS and ECMO are complex invasive therapies, their current organization and application are not based on general guidelines. In particular, the level of scientific evidence is low regarding indication, therapy initiation, and management, as well as institution-related aspects, such as main responsibility by different disciplines for separate tasks or the organization of intensive care units. In context of the multidisciplinary German guideline on “Use of extracorporeal circulation (ECLS/ECMO) for cardiac and circulatory failure,” the present survey aimed to evaluate the current status of organization and application of ECLS therapy.

**Materials and Methods**

In June 2017, a standardized questionnaire consisting of 30 items was sent to all 84 German cardiosurgical departments for evaluation of the current status of organization and application of ECLS therapy.

While the first part of the questionnaire dealt with general information about the institution and the frequency of ECLS application, the second part focused on indications and contraindications, structural organization aspects, therapy management, weaning, and adverse events.

All returned questionnaires were anonymized at first before any analysis was performed. All data were collected utilizing categorical variables, for statistical comparisons of which two-sided Fisher’s exact tests were applied. To analyze the occurrence of severe adverse events (SAE) in dependency on the ECLS center volume, for both variables (SAE and ECLS applications per year), the median value of the declared category range was assigned to each center, and the ratio SAE/ECLS value was calculated. Statistical comparison was conducted by means of a Mann–Whitney’s U test, as indicated by the Shapiro–Wilk’s test for normality. Statistical significance was assumed if p-values were less than 0.05. Data analysis was conducted with GraphPad Prism v5.04 (GraphPad Software, San Diego, United States).

**Results**

The return rate amounted to 78 out of 84 departments (92.9%) in 79 institutions, whereof 76 departments (97.4%) reported to implant ECLS devices. All percentages in the descriptive statistics are related to these 76 centers applying ECLS therapy. General characteristics are presented in **Table 1**. The range of ECLS volume per center is depicted in **Fig. 1**, while **Fig. 2** displays indications and contraindications for ECLS implantation.

**Program Structure and Responsibility**

Sixteen per cent of the departments applying ECLS reported that there is no commitment to obligatory responsibility in terms of ECLS initiation or further therapy management. Analysis of the responsibility for different ECLS-related tasks revealed that the cardiosurgical departments were involved in 98.7%, whereas further therapy management and monitoring are multidisciplinary tasks in the majority of the institutions (**Table 2**). However, application of ECLS is also initiated without cardiosurgical expertise in 46.1%, predominantly in cardiac catheterization laboratories or intensive care units. In 11.8% of the institutions, ECLS therapy is not continuously supported by clinical perfusionists. Alarmingly, in 10.7% of all centers, ECLS monitoring is performed by not specifically trained personnel. The organization of ECLS therapy was evaluated to be satisfactory (without need for substantial changes) by only 69.7% of the centers, whereas the percentage was significantly higher in departments with obligatory responsibilities of different disciplines for ECLS initiation and therapy management, as compared with those with variable responsibilities (**Fig. 3**).

**Therapy Management and Monitoring**

Cannulation via the femoral arteries is applied in all institutions, while aortic or subclavian access is conducted in 89.5 or 67.1% of the departments. Central cannulation techniques are used by 40.5% in more than 25% of their patients. Pulsatile ECLS is applied in only 13.3% of the departments, and additional circulatory support by venting the left atrium or the left ventricle in 42.1%, whereas most of these departments use it in less than 50% of their patients (**Fig. 4A**). To treat watershed phenomenon issues (Harlequin’s syndrome) in ECLS patients...
with preserved or recovered left ventricular ejection but severely impaired pulmonary gas exchange, aortic or subclavian cannulation is the favored option (► Fig. 4B). Application of anticoagulants is monitored by means of activated clotting time (ACT) in 76.3% and partial thromboplastin time (PTT) in 73.7%. Although the target values differ, the most common limits were found to be ACT > 150 seconds and PTT > 50 or > 60 second (► Fig. 5). ECLS therapy is partially conducted in spontaneously breathing and even in unsedated patients in 64.9% of the departments. The vast majority of departments (88.2%) reported the occurrence of SAE under ECLS therapy, whereas centers with more than 50 ECLS therapies per year had half the event rates as compared with centers with a caseload lower than 50 per year (► Fig. 6). To assess parameters to decide on the weaning process, most centers rely on a combination of parameters such as echocardiography (97.4%), clinical status (92.1%), hemodynamic monitoring (88.2%), and the course of catecholamine dosage (86.8%).

**Discussion**

This report provides the results of the first nationwide survey on ECLS therapy in nearly all German cardiothoracic departments. Since ECLS has become a therapeutic option in various in- and out-of-hospital scenarios, it is an expanding field in cardiovascular medicine, so that evaluation and optimization of various aspects such as indication, application, organization, and patients’ outcome are of broad interest.
Profile of the Participating Departments

Almost every participating department reported the implantation of ECLS systems. However, the majority (67.1%) implants less than one extracorporeal system per week on average. More than three out of four departments run emergency programs to initiate ECLS therapies outside of hospital and safely transfer the patients to their intensive care units. In many cases, these patients suffer from severe cardiogenic shock or cardiac arrest, and ECLS is applied shortly before or under ongoing cardiopulmonary resuscitation. If cardiac recovery is not expected and the clinical state of the patients justifies further treatment, assist device implantation or even heart transplantation may be considered. Due to the decreasing number of available donor organs in Germany, the heart and lung transplantation programs are focused on a few centers, while more than five out of six departments perform assist device implantations allowing for destination or bridge-to-transplant therapy. For patients with cardiogenic shock in in-hospital as well as out-of-hospital scenarios, and especially under resuscitation, ECLS support has the potential to improve neurological outcome and mortality, whereas particularly age, duration of resuscitation, and metabolic state have to be considered as potential contraindications.8,9,11–13

Program Structure and Responsibility

Reports on insufficient coordination, in particular regarding variable responsibility of different disciplines for ECLS
Therapy Management and Monitoring

Initiation and application of ECLS therapy differ between the participating institutions. While most departments (89.5%) apply central ECLS cannulation at least in selected patients, the strategies for left ventricular unloading and treatment of watershed phenomena are inconsistent. In terms of left ventricular unloading, central vent catheters as well as percutaneous ventricular assist devices improve the hemodynamics.\(^\text{16}\)

In German cardiosurgical departments, a pulsatile flow concept for ECLS does not exist at considerable frequency. One of the most important aspects during extracorporeal circulation therapy is monitoring of the anticoagulatory treatment. The present survey shows that there is no nationwide standard for target values that are supposed to enable a safe anticoagulation status. This finding is in line with the results from a recent meta-analysis that could not declare evidence for recommendations on anticoagulation strategies or target values.\(^\text{17}\)

In the present survey, SAE, such as unintentional decannulation, device thrombosis, pump failure, lower limb ischemia, or liver failure, were less frequent in centers with more than 50 ECLS therapies per year, whereas no statistically significant difference could be found. With regard to the weaning process, different techniques to assess the weaning potential, such as echocardiography, clinical status, hemodynamic monitoring, or the course of catecholamine dosage, are used by the majority of the centers. However, more evidence-based criteria are requested for optimization of the complex weaning process in ECLS patients.

Conclusion

According to the results of this survey, there is substantial room for further improvement concerning various aspects in the context of ECLS therapy in Germany. Moreover, current installation and actual management of extracorporeal therapies are heterogeneously conducted. Since ECLS patients suffer from severely compromised organ functions, and therefore need a continuous and at each time appropriate quality level of treatment, an evidence-based guideline is required. To address this need, an interdisciplinary German S3 guideline “Use of extracorporeal circulation (ECLS/ECMO) for cardiac and circulatory failure” is currently in preparation.

Note

This survey was conducted by the Working Group for Extracorporeal Circulation and Mechanical Circulatory Support and the board of directors of the German Society for Thoracic and Cardiovascular Surgery.

Acknowledgments

The authors did not receive funding for this project. Since both authors (A.A. and U.B.) provided major contributions to all aspects of this project, equal authorships were assigned in agreement with all co-authors.

References


Fig. 6 Occurrence of SAE in dependency on the ECLS volume. ECLS, extracorporeal life support; SAE, severe adverse events.


